Equities Analysts Offer Predictions for Immunovant, Inc.’s Q1 2026 Earnings (NASDAQ:IMVT)


Immunovant, Inc. (NASDAQ:IMVTFree Report) – Analysts at Zacks Research lowered their Q1 2026 earnings per share estimates for shares of Immunovant in a note issued to investors on Monday, April 8th. Zacks Research analyst E. Bagri now forecasts that the company will post earnings of ($0.49) per share for the quarter, down from their prior forecast of ($0.48). The consensus estimate for Immunovant’s current full-year earnings is ($1.70) per share. Zacks Research also issued estimates for Immunovant’s Q4 2026 earnings at ($0.55) EPS and FY2026 earnings at ($1.99) EPS.

Immunovant (NASDAQ:IMVTGet Free Report) last posted its earnings results on Monday, February 12th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07.

A number of other brokerages also recently issued reports on IMVT. Wolfe Research assumed coverage on Immunovant in a research report on Thursday, February 15th. They set an “outperform” rating and a $55.00 price target for the company. HC Wainwright lifted their price target on Immunovant from $47.00 to $51.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. JPMorgan Chase & Co. initiated coverage on Immunovant in a research report on Tuesday, February 20th. They set an “overweight” rating and a $51.00 price target for the company. The Goldman Sachs Group initiated coverage on Immunovant in a research report on Wednesday, March 13th. They issued a “buy” rating and a $50.00 target price for the company. Finally, Truist Financial restated a “buy” rating and issued a $48.00 target price on shares of Immunovant in a research report on Monday, March 25th. Seventeen research analysts have rated the stock with a buy rating, According to MarketBeat, Immunovant currently has a consensus rating of “Buy” and a consensus target price of $48.00.

Read Our Latest Research Report on Immunovant

Immunovant Trading Down 0.5 %

Shares of IMVT opened at $30.72 on Thursday. The company has a market cap of $4.46 billion, a PE ratio of -16.70 and a beta of 0.65. The stock has a 50-day moving average price of $33.78 and a 200-day moving average price of $36.31. Immunovant has a 12-month low of $14.11 and a 12-month high of $45.58.

Institutional Investors Weigh In On Immunovant

Several hedge funds have recently added to or reduced their stakes in IMVT. Comerica Bank bought a new stake in Immunovant in the third quarter worth $26,000. Headlands Technologies LLC bought a new stake in Immunovant in the fourth quarter worth $27,000. Ensign Peak Advisors Inc boosted its holdings in Immunovant by 72.6% in the third quarter. Ensign Peak Advisors Inc now owns 6,350 shares of the company’s stock worth $35,000 after acquiring an additional 2,670 shares in the last quarter. UBS Group AG boosted its holdings in Immunovant by 205.7% in the third quarter. UBS Group AG now owns 6,978 shares of the company’s stock worth $39,000 after acquiring an additional 4,695 shares in the last quarter. Finally, Barclays PLC boosted its holdings in Immunovant by 2,558.1% in the second quarter. Barclays PLC now owns 2,286 shares of the company’s stock worth $43,000 after acquiring an additional 2,200 shares in the last quarter. 47.08% of the stock is owned by institutional investors.

Insider Buying and Selling at Immunovant

In other news, insider Julia G. Butchko sold 1,053 shares of the business’s stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $31.18, for a total transaction of $32,832.54. Following the transaction, the insider now directly owns 461,742 shares of the company’s stock, valued at $14,397,115.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Peter Salzmann sold 4,807 shares of the company’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $31.18, for a total value of $149,882.26. Following the sale, the chief executive officer now directly owns 1,086,958 shares of the company’s stock, valued at $33,891,350.44. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Julia G. Butchko sold 1,053 shares of the company’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $31.18, for a total value of $32,832.54. Following the completion of the sale, the insider now directly owns 461,742 shares in the company, valued at $14,397,115.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,064 shares of company stock worth $612,982. 4.80% of the stock is currently owned by insiders.

Immunovant Company Profile

(Get Free Report)

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.

See Also

Earnings History and Estimates for Immunovant (NASDAQ:IMVT)



Receive News & Ratings for Immunovant Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Immunovant and related companies with MarketBeat.com’s FREE daily email newsletter.


Source link

Check Also

Equities Analysts Offer Predictions for Chubb Limited’s FY2024 Earnings (NYSE:CB)

Chubb Limited (NYSE:CB – Free Report) – Stock analysts at Zacks Research decreased their FY2024 …

Leave a Reply

Your email address will not be published. Required fields are marked *